Dermisonics, Inc.
Dermisonics, Inc.: Euro Funds Agree to Dermisonics’ Financing
Corporate-news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
Euro Funds Agree to Dermisonics’ Financing
Completion of Financing Will Establish Base for Expansion Across
Multi-Billion Dollar Cosmetic, Drug & Antiseptic Markets
Irvine, California – March 22, 2006,
(PR Newswire)
Dermisonics, Inc. (OTC Bulletin Board: DMSI.OB), a pioneer in the
development of painless injection-free ultrasonic transdermal drug-delivery
technologies with broad pharmaceutical and consumer applications, announced
today that the Company has agreed to sell a total of 7.2 million common
shares of the Company’s capital stock to two Luxembourg-based SICAV funds
for net proceeds of $4,134,240. The placement will be completed in reliance
upon the exemption from the registration requirements of the Securities Act
afforded by Regulation S as promulgated under the Securities Act of 1933.
Dermisonics will use the net proceeds derived from the financing to
continue the development and testing of the U-Strip, U-Wand and A-Wand
systems, to explore new applications for the Company’s intellectual
property estate and to negotiate strategic marketing alliances with
companies in the cosmetic, pharmaceutical, and antiseptic industries. It
is anticipated that the closing of this transaction will occur in the next
30 days.
Bruce Haglund, CEO of Dermisonics commented, “This financing will give us
the resources to complete our human pilot trials for our insulin studies
and accelerate our R&D and marketing programs simultaneously on three
critical fronts:
– The $17.6 billion skin care market and the anti-aging needs of the 270
million graying baby boomers in the U.S and Europe alone,
– The $19 billion drug delivery market treating the 55 million diabetics
worldwide forced to use painful needles to survive this debilitating
disease, and
– The $1.2 billion antiseptic market for consumers at home and to combat
the critical problem of infections for soldiers wounded on the
battlefield”.
About Dermisonics, Inc. – Dermisonics is an intellectual property company
and advanced technology incubator that is primarily focused on developing
and marketing its transdermal and subdermal technologies for applications
in the drug (U-Strip), skin care (U-Wand), and antiseptic (A-Wand) fields.
Its breakthrough system, called the U-Strip, facilitates the efficient and
needle-free delivery of drugs with large molecular structures into the
bloodstream. This system is based on a radical integration of
microelectronics and ultrasonic science with a product-carrying patch and
represents a quantum leap in non-invasive, transdermal delivery technology.
Tests have shown that the U-Strip facilitates the transdermal delivery of
Insulin as well as potentially at least 175 other existing drugs through
the pores of the skin. Conventionally available transdermal technology
cannot effectively deliver these drugs due to their large molecular size.
The Company has also developed major line extensions for applications in
the medical (Antiseptic Wand) and skin care (U-Wand) fields.
For further information contact Bruce Haglund, CEO.
bruce.haglund@dermisonics.com
Dermisonics, Inc.
2 Park Plaza, Suite 450,
Irvine, California 92614
U.S.A.
888-401-DERM (3376) Toll Free
949-733-1101 Phone
949-733-1188 Fax
North American Investor Relations Contact:
Brent Pierce, International Marketing Trend, Inc.
Phone: 877-676-4447
European Investor Relations Contact:
Michael Drepper
Phone: +49-621-430-6130
investor-germany@dermisonics.com
For additional information, please visit www.dermisonics.com
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 that are based upon current expectations or beliefs,
as well as a number of assumptions about future events. Although the
Company believes that the expectations reflected in the forward-looking
statements and the assumptions upon which they are based are reasonable, it
can give no assurance that such expectations and assumptions will prove to
have been correct. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject to
numerous factors and uncertainties, including but not limited to adverse
economic conditions, intense competition, lack of meaningful research
results, entry of new competitors and products, adverse federal, state and
local government regulation, inadequate capital, unexpected costs and
operating deficits, increases in general and administrative costs,
termination of contracts or agreements, technological obsolescence of the
Company’s products, technical problems with the Company’s research and
products, price increases for supplies and components, litigation and
administrative proceedings involving the Company, the possible acquisition
of new businesses or that result in operating losses or that do not
perform as anticipated, unanticipated losses, the possible fluctuation and
volatility of the Company’s operating results, financial condition and
stock price, losses incurred in litigating and settling cases, dilution in
the Company’s ownership of its business, adverse publicity and news
coverage, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and research
scientists, changes in interest rates, inflationary factors, and other
specific risks. In addition, other factors that could cause actual results
to differ materially are discussed in the Company’s most recent Form 10-QSB
and Form 10-KSB filings with the Securities and Exchange Commission.
(c)DGAP 22.03.2006
—————————————————————————
language: English
emitter: Dermisonics, Inc.
Dermisonics, Inc.
19428-2977 West Conshohocken, Pa. Vereinigte Staaten von Amerika
phone: +1 610-941-2780
fax: +1 610-941-2990
email: bruce.haglund@dermisonics.com
WWW: dermisonics.com
ISIN: US24983U1043
WKN: A0DK4Y
indexes:
stockmarkets: Freiverkehr in Berlin-Bremen; Open Market in Frankfurt
End of News DGAP News-Service
—————————————————————————
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found